Loading...
Market
Agios revenue growth in Q4 2024?
5
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Agios Pharmaceuticals quarterly financial report
Story
$AGIO: Agios Pharmaceuticals Announces Positive Phase 3 Results for Mitapivat in Thalassemia, 30.4% vs. 12.6%
Jun 3, 2024, 10:34 AM
Agios Pharmaceuticals ($AGIO) has announced that its Phase 3 ENERGIZE-T study of Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary endpoint and all key secondary endpoints. The study demonstrated a significant transfusion reduction response, with 30.4% of participants showing improvement compared to 12.6% in the placebo group. This positive outcome, announced on June 3, 2024, marks a potential novel advancement in care for patients with this inherited blood disorder.
View original story
Similar markets
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Below $3 billion • 25%
$3-5 billion • 25%
$5-7 billion • 25%
Above $7 billion • 25%
Below $5 Billion • 33%
$5 Billion to $10 Billion • 33%
Above $10 Billion • 33%
Less than 5% • 25%
5%-10% • 25%
10%-15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Acquisition • 33%
Partnership • 33%
None • 33%
Below $50 million • 33%
$50 million to $100 million • 33%
Above $100 million • 34%
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%